Letrozole plus SPH4336 versus letrozole alone for breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests whether adding SPH4336 to letrozole works better than letrozole plus a placebo for treating hormone-receptor–positive, HER2-negative breast cancer in people starting first-line treatment. It may help slow cancer growth more effectively if the added drug is beneficial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must voluntarily join and sign the informed consent form
- You are female, age 18 to 75
- You have breast cancer that is hormone-receptor positive and HER2 negative, and it can’t be treated with surgery or other local procedures
- You have not had prior treatment with anti-cancer medicines for advanced/metastatic disease
- You must have at least one visible measurable tumor area the study can track, plus adequate blood/organ test results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies SPH4336 given together with standard hormone (endocrine) therapy for breast cancer that has spread or cannot be treated with surgery. It aims to see whether the combination is safer and more effective than hormone therapy alone.
This trial tests whether SPH4336, added to standard hormone (endocrine) therapy, can improve outcomes for people with breast cancer that has spread to the brain. It also looks closely at safety and side effects.
This study tests a new version of the hormone therapy letrozole (Letrozole SIE) compared to the standard letrozole (Femara®), both given together with a targeted therapy called ribociclib. It is for postmenopausal women with HR-positive, HER2-negative breast cancer that has spread to other parts of the body and has not yet been treated for advanced disease.
This early-stage study tests SPH5030 tablets in people with HER2-positive advanced solid tumors that have not responded to standard treatment or have no standard option. It aims to see whether the treatment can shrink tumors and is safe enough to move forward.
This trial tests a new medicine (BGB-43395) combined with letrozole against the usual CDK4/6 inhibitor plus letrozole. It is for people with advanced or metastatic HR-positive, HER2-negative breast cancer who have not yet had treatment for advanced disease.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
Hear when a new Locally Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.